Financial press releases - Kolinpharma S.p.A

KOLINPHARMA

IT | EN | FR | ES | DE

La nostra Mission

Investor Relations
Documents for investors

Financial press releases

updated data on 06/06/2023 at 04:38

Year 2022

Published 25/10/2022 07:56	Kolinpharma® signs an important three-year agreement with the multinational Astareal® AB The commercial agreement provides the distribution of products in mainland China, Hong Kong, Macao, and Taiwan
Published 09/08/2022 20:47	MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUER’S SECURITIES pursuant to paragraph 1.4 of Annex 3F
Published 06/07/2022 09:11	Model disclosure for transactions in the issuer’s securities Pursuant to paragraph 1.4 of Annex 3F
Published 07/04/2022 22:36	Model disclosure for transactions in the issuer’s securities

Year 2021

Published
18/06/2021
10:03

Kolinpharma® launches the new product DOLTENDIX®

The new certified, patent pending food supplement formulated by Kolinpharma's internal R&D department

Year 2020

Published
30/01/2020
23:50

2020 corporate events calendar

Year 2020 Internal Dealing

Published
02/03/2020
23:18

Internal dealing – Rita Paola Petrelli – Comunicato Sdir

Year 2019

Published
29/01/2019
09:09

2019 corporate events calendar

Year 2018

Published 06/11/2018 08:14	KOLINPHARMA: the new site declined in 5 languages is online Kolinpharma's strategy continues to encourage internationalization with a portal that can reach an ever-wider number of interlocutors
Published 27/09/2018 22:01	Approval financial report at 30 june 2018 KOLINPHARMA® APPROVES THE FINANCIAL REPORT AT 30 JUNE 2018 • Production Value: up 95% • EBITDA margin 10%
Published 05/09/2018 18:13	KOLINPHARMA participates in the “Lugano Small & Mid Cap Investor Day”-21 September 2018 The road show is organized by IRTop Consulting under the patronage of Borsa Italiana
Published 07/08/2018 09:13	KOLINPHARMA® additions to the press release dated 08/06/2018 + 98% revenues in the first half of 2018 (2.7 million euros). Number of medical prescriptions up 49%
Published 06/08/2018 07:29	KOLINPHARMA +98% revenues in the first half of 2018, which amounted to 2,7 million euro Number of medical prescriptions up 49%
Published 27/07/2018 07:45	Two new agreements for KOLINPHARMA Two new agreements for KOLINPHARMA, a scientific research agreement with “La Sapienza” University and a production agreement with Nutrilinea S.r.l.
Published 11/07/2018 08:11	KOLINPHARMA: 5th in Italy in nutraceutical companies’ growth KOLINPHARMA: in 2017 the company ranks at 5th place among more than 2,000 nutraceutical companies, thanks to its revenue growth.
Published 22/06/2018 07:46	KOLINPHARMA: signed a first new factoring pro-soluto agreement up to € 2M. KOLINPHARMA: Innovative SME in nutraceutical field communicate a factoring pro-soluto agreement of 2 Eu m, subscribed with Banca IFIS S.p.A.
Published 25/05/2018 07:38	KOLINPHARMA: +46% vs. 2017 (prescriptions 1st quarter 2018), sales network strengthening and expansion abroad KOLINPHARMA: growth in medical prescriptions in the first quarter 2018 (+46% vs. 2017); the sales network is strengthened. Start the expansion process abroad with the International Manager designation
Published 08/05/2018 19:41	KOLINPHARMA: Shareholders’ Meeting approves the annual financial report 2017 Ordinary Shareholders’ Meeting of KOLINPHARMA, Innovative SME operating in the nutraceutical sector, met today at Lainate headquarters, in second calling, under the chairwomanship of Rita Paola Petrelli
Published 17/04/2018 16:16	KOLINPHARMA in press release’s relators of “Bonus Quotazione” The event, scheduled on April 18th, 2018 in Milan, is organized by IR Top Consulting and 5 listed companies on AIM Italy will participate, in addition to the Prime Minister and the Ministry of Economic Development
Published 13/04/2018 16:53	Notice Concerning the Ordinary Shareholders’ Meeting and documentation provision KOLINPHARMA S.p.A.’s shareholders are called for the Ordinary Meeting at the operational headquarters in Lainate, Corso Europa 5, for the first calling scheduled on April 30th, 2018 at 3:00 p.m..
Published 23/03/2018 06:28	KOLINPHARMA: revenue +62% and ebitda +130% in fy 2017 KOLINPHARMA, SME is an innovative company, active in nutraceutical sector. It approved the draft financial statements at December 31st, 2017, on this day.
Published 20/03/2018 07:55	Confirmed the clinical effectiveness of the food supplement XINEPA® for the treattment of peripheral neuropathies. The clinical trial of University Umberto I in Rome controlled the Xinepa® effects, patented nutraceutical product for the treatment of peripheral neuropathy that affects 7-8% over 55 years old of European population.
15/03/2018	Standard and communication notification to the public Standard and communication notification to the public about operation carried out by people with administrative, control and direction functions and their associates.
Published 13/03/2018 12:18	2018 corporate events calendar
Published 09/03/2018 01:04	Admission to negotiations on AIM Italia trading market for KOLINPHARMA S.p.A. Italian Stock Exchange published the notice about the admission of trading on AIM Italia market. First trading day on March 9th, 2018
Published 07/02/2018 17:56	The starting of the KOLINPHARMA S.p.A.'s ordinary shares placement

Investor Relations

Events and Investor day

Corporate events calendar

Financial press releases

Shareholders’ Meetings

Financial reports

Analyst coverage

Information for shareholders

Contact investor relations

“Science accuracy and listen to people”

“Science accuracy and listen to people”